First Time User? Sign Up Now
First Time User? Enroll now.
Home > Health Library > Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.
Note: Separate PDQ summaries on Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention; Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment; Ovarian Germ Cell Tumors Treatment; and Ovarian Low Malignant Potential Tumors Treatment are also available.
Evidence of Lack of Mortality Benefit Associated with Screening
Single-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)
There is solid evidence to indicate that screening women aged 55 to 74 years at average risk of developing ovarian cancer with the serum marker CA-125 (at a fixed threshold for a positive result of 35 U/mL) annually for 6 years and TVU for 4 years does not result in a decrease in ovarian cancer mortality, after a median follow-up of 14.7 years.
Magnitude of Effect: The ovarian cancer mortality rate was 3.8 deaths per 10,000 women in the screened group and 3.6 deaths per 10,000 person-years in the usual-care group, yielding a mortality rate ratio of 1.06 (95% confidence interval [CI], 0.87–1.30).
Screening with TVU alone or with multimodal screening with CA-125 levels, assessed using the Risk of Ovarian Cancer Algorithm (ROCA), with TVU
Screening with TVU alone or with multimodal screening with CA-125 levels, assessed using the ROCA, combined with TVU in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did not show a mortality benefit of screening with either approach based on a predetermined primary endpoint among women undergoing 7 to 11 screens and a median of 11.1 years of follow-up.
Magnitude of Effect: Multimodal screening was associated with a nonsignificantly lower mortality than with no screening (15% lower mortality; 95% CI, -3% to 30%; P = .10). Ultrasound only screening also resulted in nonsignificantly lower mortality (11% lower mortality; 95% CI, -7% to 27%; P = .21).
Statement of Harms
Based on solid evidence, screening for ovarian cancer results in false-positive test results. Screened women had higher rates of oophorectomy and other minor complications such as fainting and bruising.
Magnitude of Effect:
In the TVU-only arm of the UKCTOCS trial, there were 50 false-positive surgical procedures, and in the multimodality arm, there were 14 false-positive operations per 10,000 screens.
In the general population, screening is targeted to postmenopausal women, and the major complications are related to surgery. Among younger women, the potential target group among BRCA1/2 mutation carriers, oophorectomy at younger than 45 years may increase mortality secondary to cardiovascular disease. Oophorectomy, if performed among younger women, may also reduce risk of estrogen receptor–positive breast cancers, which occur with elevated frequency among carriers of BRCA2 mutations.
Incidence and Mortality
Ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.25%.
Ovarian carcinoma is the fifth leading cause of cancer death among women in the United States and has the highest mortality rate of all gynecologic cancers. It is estimated that 21,750 new cases of ovarian cancer will be diagnosed in the United States in 2020, and 13,940 women will die of this disease. Ovarian cancer incidence rates decreased by 1.6% per year from 2007 to 2016. Ovarian cancer mortality rates decreased by 2.3% per year from 2008 to 2017. The prognosis for survival from ovarian carcinoma largely depends on stage, which is strongly associated with histopathologic type. Approximately 80% of women with ovarian carcinoma have high-grade serous carcinoma, 90% of whom present with stage III or IV disease, leading to poor survival.[1,2,3]
Types of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
The term ovarian cancer encompasses a heterogeneous group of malignant tumors of ovarian origin that may arise from germ cells, stromal tissue, or epithelial tissue within the ovary. Epithelial cancers are the most common type of ovarian cancer and are further classified into five main types: high-grade serous, endometrioid, clear cell, mucinous, and low-grade serous carcinomas. Data from detailed pathology reviews of specimens removed during risk-reducing surgery from carriers of mutations in BRCA1/BRCA2 have demonstrated a putative precursor of high-grade serous carcinoma in the fimbria of the fallopian tube (serous tubal intraepithelial carcinoma [STIC]), suggesting that many carcinomas in this group previously classified as ovarian are actually tubal primary tumors. Similar lesions have been found in noncarriers of BRCA1/2 mutations, but most data from this group are limited by the presence of concurrent bulky carcinomas throughout the pelvis. STIC is not found in all cases of high-grade serous carcinoma, suggesting other possible origins of these tumors. Many endometrioid and clear cell carcinomas are postulated to arise from endometriosis, a benign lesion that may result from implantation and persistence of exfoliated menstrual endometrium.
Malignant germ cell tumors and stromal tumors such as granulosa cell tumors are rare and account for 10% or less of malignant ovarian tumors.
For a complete description of factors associated with an increased or decreased risk of ovarian cancer, refer to the Factors With Adequate Evidence of an Increased Risk of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer section in the PDQ summary on Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention for more information. Several cancer family syndromes, such as BRCA1 and BRCA2 hereditary breast-ovarian syndrome and Lynch syndrome are associated with a marked increased risk of ovarian cancer.[5,6] (Refer to the Autosomal Dominant Inheritance of Breast and Gynecologic Cancer Predisposition section in the PDQ summary on Genetics of Breast and Gynecologic Cancers for more information about these syndromes and other genetic risk factors for ovarian cancer.)
Evidence of Lack of Mortality Benefit Associated With Different Screening Modalities
Ovarian cancer often presents with persistent but vague symptoms, usually occurring after the cancer has metastasized. Some investigators have proposed the use of symptom indices as a method of screening for ovarian cancer.[7,8] Because this is not, by definition, asymptomatic screening, it is not considered further in this summary.
Gynecologic examination usually includes a manual pelvic examination, but this procedure is commonly viewed as lacking sensitivity for detection of early-stage disease.[9,10] There is no evidence for the benefit of this test for the early detection of and decreased mortality from ovarian cancer and it is not further considered.
Other screening tests include transvaginal ultrasound (TVU) and the serum cancer antigen 125 (CA-125) assay. These are often performed in combination. Several biomarkers with potential application to ovarian cancer screening are under development but have not yet been validated or evaluated for efficacy in early detection and mortality reduction.
A U.S. Food and Drug Administration Safety Communication issued in September 2016 recommends against using currently offered screening tests to screen for ovarian cancer in any population of women. Asymptomatic high-risk women who have a false-negative screening test may delay effective preventive treatments.
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
TVU (or transvaginal sonogram [TVS]) has been proposed as a screening method for ovarian cancer because of its ability to reliably measure ovarian size and detect small masses.
In the UKCTOCS, outcomes among 50,623 postmenopausal women aged 50 to 74 years who were randomly assigned to 7 to 11 rounds of annual screening with TVU alone and 50,264 who underwent multimodal screening with CA-125 testing and TVU (see below) were compared with results among 101,299 women who were not screened, which served as a comparison group. Women were recruited in 13 trial centers across the United Kingdom from 2001 to 2005. After trial initiation, but before analysis, the protocol was amended twice: 1) the study was extended to achieve greater power and 2) criteria for referral in the multimodal arm were liberalized to increase the percentage of positive screens.
TVUs were scored as normal, resulting in continued annual screening; intermediate, leading to repeat CA-125 and TVU at 3 months; or abnormal, requiring repeat testing within 6 weeks. In the TVU arm, 314 cancers were diagnosed and 154 ovarian cancer–related deaths occurred compared with the nonscreened arm, in which 630 cancers were diagnosed and 347 ovarian cancer–related deaths occurred. Mortality was nonsignificantly lower with TVU screening (11%; 95% CI, -7% to 27%; P = .21). TVU screening resulted in 50 surgeries per 10,000 women for a false-positive screen. Complications resulted from less than 1% of screens and 3.4% of operations. Over a median of 11.1 years, ovarian cancer deaths occurred among 0.30% of screened women and 0.34% of unscreened women.[12,13]
CA-125 serum testing for ovarian cancer screening
CA-125 is a tumor-associated antigen that is used clinically to monitor patients with epithelial ovarian carcinomas.[14,15] Measurement of CA-125 concentrations has been proposed as a potential marker for the early detection of ovarian cancer, either as a single test with a threshold cutpoint or in algorithms examining the change in levels over time. The two randomized trials have included CA-125 either in parallel or sequentially with TVU for multimodality screening. The most commonly reported CA-125 reference value that designates a positive screening test is 35 U/mL, and this was the reference value used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial (NCT01696994) to define an abnormal test result. The measurement of CA-125 levels, in parallel combination with TVU, is the ovarian screening intervention evaluated in the PLCO trial.[17,18] Elevated CA-125 levels are not specific to ovarian cancer and have been observed in patients with nongynecological cancers, endometriosis, liver disease, congestive heart failure, pleural or peritoneal fluid accumulation, and in the first trimester of pregnancy.[20,21] The sensitivity of the CA-125 test for the detection of ovarian cancer was estimated in two nested case-control studies using serum banks.[22,23] The sensitivity for CA-125 levels of at least 35 U/mL ranged from 20% to 57% for cases occurring within the first 3 years of follow-up; the specificity was 95%.
A phase II/III biomarker study was conducted to evaluate the sensitivity of several markers of ovarian cancer, including CA-125 concentrations, using specimens collected from ovarian cancer patients at four sites. The estimated sensitivity for early-stage disease (stage I and II ovarian cancer) was 56% (95% confidence interval [CI], 49%–72%) for a cutpoint set to obtain a fixed specificity of 95%. The threshold for the cutpoint for CA-125 at 95% specificity was 24 U/mL. For all cases (56% of cases had stage III or IV disease at diagnosis), the sensitivity was 73% (95% CI, 64%–84%). When the clinical cutpoint of 35 U/mL was used, the sensitivity decreased.
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Single-threshold CA-125 levels and TVU
The PLCO trial evaluated the effect of screening on ovarian cancer mortality among women aged 55 to 74 years on the basis of six annual screens with serum CA-125 testing at a threshold for positive of 35 U/mL and four annual screens with TVU. Women were randomly assigned to screening (n = 39,105) or usual care (n = 39,111) at ten screening centers across the United States between November 1993 and July 2001. Participants and their health care practitioners received the screening test results and managed evaluation of abnormal results. The usual-care group was not offered screening with CA-125 or TVU but received their usual medical care. Participants were initially monitored for a maximum of 13 years (median, 12.4 years; range, 10.9–13.0 years) for cancer diagnoses and death until February 28, 2010. Mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers, was the main outcome measure. Secondary outcomes included ovarian cancer incidence and complications associated with screening examinations and diagnostic procedures. After transition of PLCO trial participants to a centralized follow-up process, follow-up for mortality was extended until the end of 2012, for a maximum of 19.2 years and a median of 14.7 years.
Compliance with screening ranged from 85% at the initial round to 73% at the sixth round, while contamination in the usual-care group ranged from about 3.0% for CA-125 to 4.6% for TVU. Across the first four screening rounds, 11.1% of women had at least one positive test, 8.1% had at least one positive TVU, and 3.4% had at least one positive CA-125 test. The yields of both tests were similar. Ovarian cancer was diagnosed in 212 women (5.7 per 10,000 person-years) in the intervention group and 176 women (4.7 per 10,000 person-years) in the usual-care group (rate ratio, 1.21; 95% CI, 0.99–1.48). The stage distributions were similar by study group, with stage III and IV cancers comprising the majority of cases in both the intervention group (163 cases, 77%) and the usual-care group (137 cases, 78%). The cancer case treatment distributions were very similar between groups within each stage. Through the original period of follow-up (maximum, 13 years), 118 deaths were caused by ovarian cancer (3.1 per 10,000 person-years) in the intervention group and 100 deaths were caused by ovarian cancer (2.6 per 10,000 person-years) in the usual-care group (mortality rate ratio, 1.18; 95% CI, 0.82–1.71). Through the extended follow-up period (median, 14.7 years; maximum, 19.2 years), 187 deaths were caused by ovarian cancer (3.8 per 10,000 person-years) in the intervention group and 176 deaths were caused by ovarian cancer (3.6 per 10,000 person-years) in the usual-care group (mortality rate ratio, 1.06; 95% CI, 0.87–1.30). Of the 3,285 women with false-positive results, 1,080 underwent surgical follow-up. Of the 1,080 women who underwent surgical follow-up, 163 women experienced at least one serious complication (15%). A total of 1,771 women in the intervention group (7.7%) and 1,304 in the usual-care group (5.8%) reported oophorectomy. There were 2,924 deaths resulting from other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10,000 person-years) in the intervention group and 2,914 such deaths (76.2 per 10,000 person-years) in the usual-care group (rate ratio, 1.01; 95% CI, 0.96–1.06).[25,27]
In the PLCO trial, women with visualized ovaries were at slightly higher risk of ovarian cancer (hazard ratio, 1.42; 95% CI, 1.00–2.01) than were women who had nonvisualized ovaries. A nested analysis found that ovarian volume increases were detectable 1 to 2 years before diagnosis, but the magnitude of change did not appear translatable to clinical management. Thus, among women in the general U.S. population, simultaneous screening with CA-125 and TVU did not reduce ovarian cancer mortality when compared with usual care.
The Shizuoka Cohort Study of Ovarian Cancer Screening randomly assigned women to either a screening group (n = 41,668) or a control group (n = 40,799) between 1985 and 1999 at 212 hospitals in the Shizuoka prefecture of Japan. The screening protocol comprised ultrasound and CA-125 tests annually. Women with abnormal findings were referred to a gynecological oncologist. Ovarian cancer diagnoses were determined by record linkage to the Shizuoka Cancer Registry in 2002. The annual death certificate file in Shizuoka was checked to ascertain vital status. The mean follow-up time was 9.2 years, and the mean number of screens per woman was 5.4. There were 35 ovarian cancers detected in the screening group and 32 in the control group, with a nonstatistically significant difference in the stage distribution. Nine percent of regular screening attendees had at least one false-positive result. Mortality results from this trial are not available.
Ovarian cancer screening using CA-125 analyzed according to the Risk of Ovarian Cancer Algorithm (ROCA) for a positive test result in combination with TVU
The UKCTOCS trial evaluated longitudinal CA-125 measurements using the ROCA, which defines a positive test as a statistically significant increase in a woman's serial measurements based on the algorithm, irrespective of the absolute level. The goal of this approach is to detect cancers earlier by identifying subtle within-person changes. The UKCTOCS multimodal screen incorporated a two-stage approach with ROCA as the primary screen and TVS as a secondary screen (based on results of the ROCA) for its impact on ovarian cancer mortality compared with observation without screening. Of 50,078 women in the multimodality screening arm, 338 were diagnosed with ovarian cancer and 148 died of the disease. Multimodal screening detected 40% of ovarian cancers at stage I, II, or IIIA, whereas in the arm without screening, 26% were diagnosed at these stages (P < .0001). In this arm, less than 1% of screens led to complications and 3.1% of women developed surgical complications. Using multimodal screening, 14 per 10,000 screens led to surgery for a false-positive result. At the median follow-up of 11.1 years, there were 0.29% deaths with this screening method as compared with 0.34% in the observation arm. The primary endpoint of mortality reduction with screening based on Cox regression analysis indicated a statistically nonsignificant mortality reduction of 15% (95% CI, -3% to 30%; P = .10). The trial conducted a pre-specified analysis in which cases considered prevalent based on CA-125 levels at baseline were omitted. This subset analysis found a significant reduction in mortality of 20% (95% CI, -2% to 40%, P = .021), compared with observation.
A post hoc nested study was conducted within the PLCO trial to determine if the use of ROCA could potentially improve the identification of early-stage (stage I and stage II) ovarian cancer. The study evaluated the potential impact under two scenarios: best case and stage shift. Best-case scenario assumed that all cancers that would have been detected earlier with ROCA than with single-threshold CA-125 concentrations would have avoided mortality. The stage-shift scenario applied the observed PLCO early-stage survival rates to cases detected at an earlier stage with ROCA. The risk of death from ovarian cancer with ROCA was lower but estimates were not statistically significant (relative risk [RR] of 0.90 for best-case scenario [95% CI, 0.69–1.17] and RR of 0.95 for stage-shift scenario [95% CI, 0.74–1.23]).
Another retrospective study using annual CA-125 concentrations from the PLCO trial examined the potential impact of parametric empirical Bayes (PEB) longitudinal algorithm for the earlier detection of 44 incident ovarian cancers identified in the PLCO trial. Setting the specificity at 99%, PEB signaled "abnormal" CA-125 concentrations on average 10 months earlier than with the single-threshold cutpoint. Whether this translated into a mortality benefit could not be determined.
CA-125 velocity has also been examined using a multiple logistic regression model within the PLCO trial as a predictor for the development of ovarian cancer. Both CA-125 velocity and time intervals between screening tests were associated with the development of ovarian cancer. The risk of ovarian cancer increased as velocity (measured as U/mL per month) increased, and the risk of ovarian cancer decreased when the time intervals between screening tests increased.
Other Potential Markers
Research continues to find other biomarkers that either alone or in combination with CA-125 concentrations may lead to the early detection of ovarian cancer. A panel of biomarkers that included CA-125, HE4, transthyretin, CA15.3, and CA72.4 was evaluated using specimens assembled from multiple cohort and randomized trials, including the PLCO trial. The phase II and III biomarker studies concluded that CA-125 remained the "single-best biomarker" for ovarian cancer. Another retrospective study, nested within the PLCO trial and included 118 ovarian cancer cases and 8 controls per case, evaluated seven proteomic biomarkers (apolipoprotein A1, truncated transthyretin, transferrin, hepcidin, beta-2 microglobulin, connective tissue activating protein III, and inter-alpha-trypsin inhibitor heavy-chain) in addition to CA-125. The addition of the seven protein biomarkers to CA-125 did not improve the sensitivity beyond the use of CA-125 levels alone. This contrasted with this same group's preliminary evaluation of these markers using postdiagnostic rather than prediagnostic blood samples.
Harms of Screening
The PLCO trial provides the most reliable data to date on screening-related harms. The rate of minor complications associated with CA-125 and TVU, such as bruising or fainting, occurred at a rate of 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with TVU. Major complications associated with the diagnostic procedures among women diagnosed with ovarian cancer included infections, blood loss, bowel injury, and cardiovascular events. At least one major complication was reported among 52% of women diagnosed in the usual-care group and 45% among women diagnosed with ovarian cancer in the screened group.
False-positive tests occurred among 3,285 women, translating to a rate of about 5% at each screening round. Most false-positive tests (60%) resulted from TVU. Of the 3,285 women with false-positive results, 33% underwent surgery. Of the 1,080 women who underwent surgery, 15% had 222 major complications, for a rate of 20.6 complications per 100 surgical procedures.
Women in the intervention group were more likely to have had an oophorectomy than those in the control group. Rates of oophorectomy were 85.7 per 10,000 person-years in the screened group, compared with 64.2 per 10,000 person-years in the usual-care group (rate ratio, 1.33; 95% CI, 1.24–1.43).
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Description of the Evidence
Revised text to state that ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.25% (cited Howlader et al. reference 1).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian, fallopian tube, and primary peritoneal cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."
The preferred citation for this PDQ summary is:
PDQ® Screening and Prevention Editorial Board. PDQ Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389336]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website's Email Us.
Last Revised: 2020-04-20
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.